Clinical Trials Logo

Functional Dyspepsia clinical trials

View clinical trials related to Functional Dyspepsia.

Filter by:

NCT ID: NCT01919021 Completed - Clinical trials for Functional Dyspepsia

Assessment of Gastro-Intestinal Function to a Mixed Meal by Non-invasive Imaging

Start date: April 2011
Phase: N/A
Study type: Interventional

Dyspeptic symptoms, such as pain after eating, bloating and nausea all have major impact on quality of life and health care costs. When no structural cause is identified, patients are diagnosed with functional dyspepsia. This trial aims to identify objective abnormalities of stomach function that explain patient's symptoms and establish diagnosis. Another group are diabetic patients who can often develop similar symptoms, labelled as diabetic gastroparesis. In some cases this is associated with delayed gastric emptying but not all. 24 patients with functional dyspepsia will be studied and 24 healthy controls (to establish normal ranges) and 24 diabetic patients with symptoms of functional dyspepsia. The utility of 3 different non-invasive investigations will be assessed. At screening the nutrient drink test (NDT) asks the patient to drink 40ml of milkshake (0.75kcal/ml) every minute and score symptoms every 5 minutes. The patient continues until they reach the maximum tolerated volume. Participants will then be randomized to undergo non-invasive imaging on two separate test days by magnetic resonance imaging (MRI) and gastric scintigraphy MRI will be completed with the patient ingesting 400ml of milkshake (identical to NDT) and 12 agar beads (no additional calories) of known breaking strength. The emptying of the stomach will be visualised with the MRI alongside symptom recording. Gamma scintigraphy will ingest the same meal as for the MRI scan but radioactive labelling will allow the rate of liquid and solid meal emptying to be visualised alongside symptom recording. Additionally, blood sugars will be recorded before nutrient drink test and at 15 and 30 minutes following ingestion of 400ml of milkshake and 12 agar beads. Data will be analyzed to assess the association of objective abnormalities of gastric function and patient symptoms. Additionally the results of non-invasive imaging by MRI and GS will be compared to assess the optimal measurement of gastric function and emptying in this clinical scenario.

NCT ID: NCT01822470 Enrolling by invitation - Clinical trials for Functional Dyspepsia

Small Intestinal Bacterial Overgrowth: A Prospective Registry

SIBO
Start date: January 2013
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to investigate the prevalence of small intestinal bacterial overgrowth (SIBO) in patients who will be undergoing an enteroscopy as an outpatient procedure with symptoms of functional dyspepsia. In addition, the investigators would like to identify the types of bacteria that are present in the small intestines in patients with SIBO and compare two different diagnostic tools: microbiologic culture and DNA sequencing of bacteria. The aim is to compare the microbiota between patients with and without the clinical complications of SIBO

NCT ID: NCT01817465 Completed - Clinical trials for Functional Dyspepsia

A Study to Demonstrate the Efficacy and Safety of Motilitone®

Start date: August 2012
Phase: Phase 4
Study type: Interventional

This is a phase IV , comparative study to evaluate the efficacy and safety of Motiltone® in treatment of the patients with functional dyspepsia. The study is conducted with following methods: multi-centers, double blind, randomization, parallel. The subjects will receive Motilitone® or/and Pantoline®.

NCT ID: NCT01671670 Completed - Clinical trials for Functional Dyspepsia

Acupuncture for Patients With Function Dyspepsia

Start date: September 2012
Phase: Phase 2/Phase 3
Study type: Interventional

Hypothesis: Acupuncture is efficacious and safe for patients with functional dyspepsia Design: - A single blind randomized controlled trial - 200 participants will be included - Two arms: acupuncture and sham acupuncture group

NCT ID: NCT01668927 Completed - Clinical trials for Functional Dyspepsia

Empirical Rescue Therapies of Helicobacter Pylori Infection

Start date: July 2012
Phase: Phase 4
Study type: Interventional

The increase of antibiotic resistance to H. pylori causes failure of treatment. Furazolidone, amoxicillin and tetracycline are good candidates for rescue therapy since resistance to these three antimicrobials was rare. It is necessary to assess the efficacy and safety of these four bismuth-containing quadruple regimens with above antibiotics as empirical rescue therapies for H. pylori eradication.

NCT ID: NCT01667718 Completed - Clinical trials for Functional Dyspepsia

Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment

Start date: May 2012
Phase: Phase 4
Study type: Interventional

To examine and compare the efficacy of 2 week Levofloxacin-containing therapies with and without Bismuth for H.pylori treatment.

NCT ID: NCT01667575 Completed - Clinical trials for Functional Dyspepsia

Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori

Start date: August 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to observe the efficacy of ten day triple therapy-based, bismuth-containing quadruple therapy for H.pylori treatment.

NCT ID: NCT01643083 Completed - Clinical trials for Functional Dyspepsia

Rifaximin for Functional Dyspepsia

Start date: January 2013
Phase: Phase 2/Phase 3
Study type: Interventional

Functional dyspepsia is a very common medical condition, which occurs in up to 30% of people in the community. However, results of current pharmacological treatment on functional dyspepsia are unsatisfactory. Rifaximin is a minimally absorbed antibiotic that has been used in treatment of non-constipated irritable bowel syndrome (IBS). In particular, bloating and abdominal pain was improved by rifaximin treatment in this group of IBS patients. Whilst there is considerable overlap in symptoms of functional dyspepsia and IBS, the investigators test whether rifaximin is also effective in curing post-prandial distress symptoms related to dyspepsia.

NCT ID: NCT01591174 Completed - Clinical trials for Functional Dyspepsia

Ghrelin and Gastric Emptying in Children With Functional Dyspepsia

GHR
Start date: May 2012
Phase:
Study type: Observational

The purpose of this research is to see if there are differences between children who have FD and children without FD in the ability of the stomach to empty food and/or in ghrelin hormone levels before and after eating. Chronic abdominal pain is the most common persistent pain condition in children and adolescents. One of the most often diagnosed types of abdominal pain is functional dyspepsia (FD). FD is abdominal pain or discomfort (e.g., nausea, bloating) in the upper abdomen that does not get better by having a bowel movement. One possible explanation for having FD is a delay in the emptying of food from the stomach, or delayed gastric (stomach) emptying. Failing to empty the stomach quickly enough may result in the feeling of being full and cause symptoms of bloating, nausea, vomiting and pain. Further, hormonal changes occur before, during, or after eating food that appear to impact stomach emptying. One of the hormones that changes with meals is called ghrelin. The relationship between ghrelin and stomach emptying needs to be explored more in children with FD. Better understanding of what causes FD symptoms may help us to improve treatment for this condition.

NCT ID: NCT01513785 Completed - Clinical trials for Functional Dyspepsia

New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection:a Pilot Study

Start date: April 2011
Phase: Phase 2
Study type: Interventional

The efficacy of traditional triple therapy has been decreased to such an unacceptable level as 70% in many areas. The study is based on the hypothesis: the most important factors which influence the effect of Helicobacter pylori (H. pylori) eradication included acid suppression intensity and sensitivity of antibiotics. So the investigators chose dual therapy because it is simple and verified to be useful. Rabeprazole, as a new proton pump inhibitor (PPI), is reported to be less susceptible to the influence of genetic polymorphisms for CYP2C19. So it has a greater and faster acid suppression effect compared to other PPIs. Amoxicillin is one of effective antibiotics to H. pylori with few side effects. The antibiotic resistance of Amoxicillin is no more than 3% in China. The purpose of our trial is to evaluate and compare the efficacy and safety of dual therapy regimens with different doses of Rabeprazole for initial treatment of H. pylori infection.